Does Glycine Recovery Randomized Trial work?

The current Migaku evidence database contains 2 reusable source documents for Glycine Recovery Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove. - There are currently no approved pharmacotherapies to treat cognitive impairment associated with schizophrenia (CIAS). [Nagy P (2026); evidence level 2] - Iclepertin (BI 425809) is a selective glycine transporter-1 (GlyT1) inhibitor that was investigated for the treatment of CIAS. [Nagy P (2026); evidence level 2] - 1 Aging is characterized by progressive physiological decline, including loss of skeletal muscle mass and function (Sarcopenia), reduced mitochondrial efficiency, and increased oxidative stress, all of which contribute to frailty and diminished quality of life in older adults (). [Wang Xiaolan (2026); evidence level 3] - 1 2 3 4 5 By the age of 70, individuals may experience a 25%−30% reduction in muscle mass, which is strongly associated with impaired mobility, falls, and loss of independence (). [Wang Xiaolan (2026); evidence level 3] - Low circulating glycine levels have been associated with insulin resistance, obesity, and higher cardiometabolic risk (,). [Wang Xiaolan (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.